Vifor Pharma and Fresenius Kabi Collaborate to Establish Joint Venture in China
Shots:
- The companies partnered to form JV focusing on the marketing, market access, and medical affairs activities for the IV iron portfolio. Vifor Pharma will own 55% while the Fresenius Kabi retains 45% of the new JV and is responsible for the commercialization of IV iron portfolio in China
- The new JV will combine Vifor’s iron deficiency portfolio with Fresenius Kabi’s commercial presence in China and will focus on patient blood management (PBM) benefiting patients and HCPs
- Vifor Pharma’s IV iron therapies are an innovative therapeutic option, allowing the effective management of patient’s blood and are used to treat IDA and other therapeutic areas
Click here to read full press release/ article | Ref: Vifor Pharma | Image: Global pharma update